Standard Life Aberdeen plc purchased a new stake in ABIOMED, Inc. (NASDAQ:ABMD) in the 4th quarter, Holdings Channel reports. The institutional investor purchased 107,279 shares of the medical equipment provider’s stock, valued at approximately $20,107,000.
Other hedge funds also recently modified their holdings of the company. State of Tennessee Treasury Department bought a new stake in shares of ABIOMED in the third quarter valued at approximately $5,058,000. Hamilton Lane Advisors LLC raised its position in ABIOMED by 50.8% during the fourth quarter. Hamilton Lane Advisors LLC now owns 23,241 shares of the medical equipment provider’s stock valued at $4,356,000 after purchasing an additional 7,827 shares in the last quarter. Pratt Collard Advisory Partners LLC acquired a new position in ABIOMED during the fourth quarter valued at approximately $412,000. Janney Montgomery Scott LLC raised its position in ABIOMED by 46.3% during the third quarter. Janney Montgomery Scott LLC now owns 2,903 shares of the medical equipment provider’s stock valued at $489,000 after purchasing an additional 919 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new position in ABIOMED during the third quarter valued at approximately $1,530,000. Institutional investors and hedge funds own 86.99% of the company’s stock.
Several research analysts have commented on ABMD shares. Guggenheim restated a “buy” rating and set a $280.00 price objective on shares of ABIOMED in a research report on Friday, February 2nd. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price objective for the company in a research report on Tuesday, November 7th. SunTrust Banks restated a “buy” rating and set a $195.00 price objective on shares of ABIOMED in a research report on Wednesday, November 1st. Jefferies Group restated a “buy” rating and set a $300.00 price objective on shares of ABIOMED in a research report on Thursday, February 1st. Finally, BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $288.86.
ABIOMED (NASDAQ:ABMD) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.20. The company had revenue of $154.00 million during the quarter, compared to the consensus estimate of $154.00 million. ABIOMED had a net margin of 16.58% and a return on equity of 15.54%. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.34 earnings per share. equities research analysts forecast that ABIOMED, Inc. will post 2.3 EPS for the current fiscal year.
In other news, VP Andrew J. Greenfield sold 20,000 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $270.36, for a total transaction of $5,407,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 7.00% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Standard Life Aberdeen plc Purchases Shares of 107,279 ABIOMED, Inc. (ABMD)” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3228898/standard-life-aberdeen-plc-purchases-shares-of-107279-abiomed-inc-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.